NLRP3 and inflammatory bowel disease: Considering that the use of curcumin (Gong et al., 2015; Iqbal et al., 2018; Wang et al., 2018), an agent inhibiting NLRP3 inflammasome and NF-κB activation, in UC patients was linked to clinical improvement and endoscopic remission, C646 may have potential in clinical studies for IBD treatment, but we still need more clinical data to test.